A detailed history of Aqr Capital Management LLC transactions in Geron Corp stock. As of the latest transaction made, Aqr Capital Management LLC holds 226,742 shares of GERN stock, worth $757,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares
226,742
Previous 41,245 449.74%
Holding current value
$757,318
Previous $174,000 491.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.17 - $4.99 $773,522 - $925,630
185,497 Added 449.74%
226,742 $1.03 Million
Q2 2024

Aug 14, 2024

BUY
$3.1 - $5.09 $127,859 - $209,937
41,245 New
41,245 $174,000
Q4 2023

Feb 14, 2024

SELL
$1.74 - $2.31 $82,202 - $109,131
-47,243 Reduced 61.17%
29,992 $63,000
Q3 2023

Nov 14, 2023

SELL
$2.11 - $3.28 $74,905 - $116,440
-35,500 Reduced 31.49%
77,235 $163,000
Q2 2023

Aug 14, 2023

BUY
$1.97 - $3.69 $1,914 - $3,586
972 Added 0.87%
112,735 $361,000
Q1 2023

May 15, 2023

BUY
$2.14 - $3.4 $55,560 - $88,274
25,963 Added 30.26%
111,763 $242,000
Q4 2022

Feb 14, 2023

BUY
$2.03 - $2.42 $55,079 - $65,661
27,133 Added 46.25%
85,800 $207,000
Q3 2022

Nov 14, 2022

BUY
$1.67 - $2.94 $97,973 - $172,480
58,667 New
58,667 $137,000
Q1 2021

May 17, 2021

SELL
$1.52 - $2.1 $81,408 - $112,471
-53,558 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$1.59 - $2.19 $85,157 - $117,292
53,558 New
53,558 $93,000
Q1 2019

May 14, 2019

SELL
$1.01 - $1.83 $101,588 - $184,066
-100,583 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$1.76 - $6.38 $33,432 - $121,194
18,996 Added 23.28%
100,583 $177,000
Q2 2018

Aug 14, 2018

BUY
$3.29 - $4.82 $268,421 - $393,249
81,587 New
81,587 $280,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.26B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.